Form 8-K - Current report:
SEC Accession No. 0001628280-25-037601
Filing Date
2025-08-05
Accepted
2025-08-05 07:18:45
Documents
13
Period of Report
2025-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K espr-20250805.htm   iXBRL 8-K 25557
2 EX-99.1 a991q22025earningsrelease.htm EX-99.1 92124
  Complete submission text file 0001628280-25-037601.txt   248880

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT espr-20250805.xsd EX-101.SCH 1798
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT espr-20250805_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT espr-20250805_pre.xml EX-101.PRE 13060
15 EXTRACTED XBRL INSTANCE DOCUMENT espr-20250805_htm.xml XML 2835
Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Filer) CIK: 0001434868 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)